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The four-transmembrane protein epithelial membrane protein-2 (EMP2) was recently identified as an endometrial protein necessary for blastocyst
implantation, but the mechanism of this role is uncertain. In other cell types, EMP2 controls delivery of certain classes of proteins to the cell surface,
including various integrin isoforms (a class of receptors implicated in endometrial–blastocyst interaction). Since avh3 integrin is an important
endometrial molecule involved in blastocyst interaction, we evaluated the role of EMP2 inmodulating integrin expression in the HEC1A endometrial
cell line and endometrial epithelium in vivo. Elevation of EMP2 expression in HEC1A cells selectively increased the expression of avh3 integrin on
the plasma membrane and was functional as judged by increased cell binding to an avh3 ligand, fibronectin. Conversely, reduction in EMP2
expression using an EMP2 specific ribozyme decreased the cellavh3 surface expression. The influence of EMP2 onavh3 integrin was also observed
in vivo as reduction of EMP2 using ribozymes or short hairpin RNA diminished avh3 integrin expression in glandular and luminal uterine
epithelium. Colocalization and coimmunoprecipitation studies suggested that EMP2 and avh3 integrin predominantly exist in a physically
associated state. This study demonstrates for the first time the influence of EMP2 on avh3 surface expression and suggests that surface trafficking of
integrin avh3 by EMP2 during the window of implantation may be a mechanism for its requirement in endometrial–blastocyst interaction.
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Implantation involves a complex sequence of cell–cell
interactions, cell adhesion events, and cellular activation events.
For endometrial cells, hormonal and local signals instruct them
to acquire receptivity during the brief implantation window. This0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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Abbreviations: 4-TM, four-transmembrane, tetraspan proteins; EMP2,
epithelial membrane protein-2; MFI, mean fluorescence intensity; pc, postco-
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jbraun@mednet.ucla.edu (J. Braun).implies the existence of a biologic process, regulated by these
hormonal and local signals, that orchestrates the dramatic
change in surface molecules displayed by endometrial cells
during the implantation window. To date, only a few endometrial
factors have been found to facilitate embryo attachment, notably
integrins. Immunohistochemical studies have shown that avh3,
a4h1, and a1h1 are present on the apical side of the luminal
epithelium during the window of implantation (Basak et al.,
2002; Lessey, 2002; Lessey et al., 2000). In particular, avh3
integrin represents a putative receptor for blastocyst attachment
as it binds to ligands such as osteopontin, and neutralizing
antibodies to avh3 prevented blastocyst implantation in mice
(Illera et al., 2000, 2003).
A new molecule necessary for successful implantation is the
four-transmembrane protein epithelial membrane protein 2
(EMP2). EMP2 is a member of the GAS3/PMP22 subfamily,87 (2005) 336 – 345
www.e
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three subfamilies of the large four-transmembrane (4-TM)
family. EMP2 is usually restricted to the cytoplasm of the
endometrial epithelium but translocates to the apical surface
during the window of implantation. Moreover, inhibition of
EMP2 expression in mice prevented blastocyst attachment to
endometrial cells and implantation in the native endometrium,
pointing to its role in endometrial competence for blastocyst
interaction (Wadehra et al., submitted for publication).
Previous studies in other cell types have shown that EMP2
modulates the surface expression of integrins, MHC class I,
and GPI-linked proteins and targets them to lipid raft
microdomains (Wadehra et al., 2002b, 2003a, 2004). Our
hypothesis is that EMP2 regulates the delivery of critical cell
surface proteins required for effective endometrial–blastocyst
interaction. In this fashion, EMP2 might provide an elegant
biochemical switch for the properly timed uterine epithelial
response required for implantation competence.
The present study examines the regulation of integrins by
EMP2 in the human endometrial cell line HEC1A. EMP2
expression was modulated by ectopic overexpression or
ribozyme-mediated inhibition. EMP2 overexpression selec-
tively upregulated both the protein and steady state RNA
levels of avh3 integrin, associated with a functional augmen-
tation of avh3-mediated binding to the extracellular matrix
fibronectin. In contrast, reduction in EMP2 expression by
ribozymes or short hairpin RNA (shRNA) decreased avh3
integrin expression both in vitro and in vivo. Colocalization
and coimmunoprecipitation studies suggested that EMP2 and
avh3 integrin exist in physically associated complexes. These
observations reflect an important role for EMP2 in the
regulation of an integrin-mediated cellular phenotype and
provide a potential mechanism for the role of EMP2 in
implantation.
Materials and methods
Animals
All animals used in this study were maintained in accordance with the
National Academy of Science Guide for the Care and Use of Laboratory
Animals , with a controlled light schedule (14L:10D) and controlled
temperature range. Female CF-1 mice (Harlan Sprague–Dawley, Indianapo-
lis, Indiana) were superovulated by IP administration of 1 IU pregnant
mare’s serum gonadotropin (PMSG; Calbiochem, San Diego, California)
followed 48 h later by 5 IU human chorionic gonadotropin (hCG; Sigma, St.
Louis, Missouri) and then housed individually with single B6D2F1/J males
(Jackson Laboratory, Bar Harbor, Maine) overnight. Only females with
evidence of a vaginal plug the following morning were utilized for
subsequent experiments; the day of the vaginal plug was recorded as
postcoital (pc) day 1.
EMP2 constructs
Ribozymes
Hammerhead ribozymes were created to cleave the mouse or human
EMP2 transcripts. The murine EMP2 hammerhead ribozyme, inserted into
pEGFP-N3, was designated pEGFP-mRZ1 (Wadehra et al., 2002b). The
hRZ2 construct targeting human EMP2 consisted of complementary 42 bp
oligonucleotides containing 22 bases of the hammerhead ribozyme
conserved catalytic core and two 10 nucleotide human EMP2 recognitiondomains (based on nucleotides 376–396 of the human EMP2 sequence;
GenBank accession no. NM001424) (Wadehra et al., submitted for
publication). Both ribozyme sequences reduced EMP2 expression in HEC1A
cells under transient and stable transfection conditions. However, the hRZ1
ribozyme sequence was more potent (¨2-fold) for EMP2 knockdown in
transient transfection (Wadehra et al., submitted for publication), whereas the
hRZ2 ribozyme sequence was similarly more potent for stable transfection. The
reasons for these differences are uncertain but might reflect greater intracellular
stability of the hRZ1 sequence under transient conditions and more efficient
genomic integration of the hRZ1 sequence for stable transfection.
hRZ2a: 5V-GAAAGGACGAAACCGCCTGCAAACTTGTTTATTG-
CAGCTTAT-3V
hRZ2s: 5V-GGACTCATCAGCAGGCCACCAAACAACAACAATTG-
CATTCAT-3V
These oligonucleotides were phosphorylated, hybridized, and ligated into the
unique HpaI site located in the 3VUTR of the green fluorescent protein gene in
plasmid pEGFP-N3 (Clontech, Palo Alto, CA); the resulting plasmid was
designated pEGFP-hRZ2.
Hairpin RNAs
As a second reagent to reduce EMP2 expression, a hairpin RNA targeting
construct was produced. PCR SHAGging was used to generate RNA
polymerase III (U6 snRNA promoter)-driven constructs expressing 29 bp
shRNA targeting mouse or human EMP2 (www.cshl.org/public/SCIENCE/
hannon.html). The human U6 promoter from pGEM-Zeo-U6 (generous gift of
Gregory Hannon, Cold Spring Harbor Laboratory, Cold Spring, NY) was
amplified using a forward primer 5V-GATTTAGGTGACACTATAG-3V (SP6
promoter sequence) and one of two reverse primers (shRNA sequences
underlined, U6 promoter sequences in bold):
Mouse EMP2 (targets nucleotides 260–288; GenBank accession no.
NM007929): 5V-AAAAAAAACACGATGCGGAAGACAATAAT-
GAAGACCAAGCTTCGCCTTCATCATTGTCTTCCACATCG-
TGTCGGTGTTTCGTCCTTTCCACAA-3V
Human EMP2 (targets nucleotides 508–536; GenBank accession no.
NM001424): 5V-AAAAAAAGAAGCCGCAATCATAACACACA-
GACACGCAAGCTTCCATGTCTGTGTGTCATGATTGCGGCCTCCGGT-
GTTTCGTCCTTTCCACAA-3V
PCR was performed using puReTaq Ready-To-Go PCR Beads (Amer-
sham Biosciences, Piscataway, NJ) in a 25-Al reaction as follows: an initial
denaturation step at 95-C for 5 min followed by 30 cycles at 95-C for 30
s, 52-C for 30 s, and 72-C for 20 s, and then 72-C for 5 min. The PCR
product was TA-cloned into pCR II (Invitrogen, Carlsbad, CA). The
resulting constructs targeting mouse or human EMP2 were designated m-
shRNA and h-shRNA.
EMP2-GFP
To ectopically increase the expression of human EMP2, the complete
human EMP2 open reading frame was generated using primers bearing
flanking EcoRI sites (underlined), inclusive of the native translational start
site (bold):
5V primer: CGGAATTCCACCATGTTGGTGCTTCTTGCTTT
3V primer: CCGGAATTCACTTTGCGCTTCCTCAGTATCAG
PCR products were EcoRI-digested and subsequently cloned in frame with
GFP in the EGFP-N3 expression vector. This human EMP2-GFP fusion protein
expression vector was designated pEGFP-hEMP2.
All constructs were verified by DNA sequencing (Davis Sequencing
Facility, UC Davis), and plasmid DNA for transfection was column purified
(Qiagen, Valencia, CA).
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HEC1A cells (ATCC, Manassas, VA) were cultured in McCoys 5a medium
(GIBCO BRL, Grand Island, NY) supplemented with 10% fetal calf serum
(FCS, Hyclone, Logan, UT), 2 mM l-glutamine, 1 mM sodium pyruvate, 100
U/ml penicillin, and 100 Ag/ml streptomycin (all from Invitrogen). Stable
transfectants of HEC1A were produced with pEGFP-hEMP2 for overexpres-
sion, pEGFP-hRZ2 for EMP2 knockdown, and pEGFP-N3 as a control. These
transfectants were designated HEC1A-hEMP2, HEC1A-hRZ2, and HEC1A-
GFP, respectively. HEC1A cells were transfected using FuGENE 6 (Roche
Molecular Biochemicals). Stable clones were selected using Geneticin (800 Ag/
ml, Invitrogen) followed by flow sorting of GFP-positive cells. All cells were
grown at 37-C in a humidified, 5% CO2 atmosphere.
Antibodies
Rabbit polyclonal anti-human and mouse EMP2 antibodies were previously
described (Wadehra et al., 2003b; Wang et al., 2001). Monoclonal antibodies
(mAbs) specific for mouse a6 (clone G0H3), avh3 (clone 23C6), a1 (clone
SR84), a5 (clone 5H10–27), h1 (clone 9EG7 and 18), and h3 (clone 1)
integrin isoforms were obtained from BD Biosciences (San Diego, CA). A
rabbit antibody specific for mouse h3 integrin was obtained from Chemicon
(Temecula, CA). R-PE-conjugated antibodies specific for rat Ig, n light chain or
mouse IgG were from BD Biosciences.
Adhesion assays
A standard static adhesion assay (15–20 min) was performed as previously
described (Wadehra et al., 2002b). Briefly, 96-well plates were precoated
overnight with 10 Ag/ml laminin, fibronectin, or poly-d-lysine (RocheMolecular
Biochemicals, Indianapolis, Indiana) or with 1% fatty acid free BSA (Sigma
Chemicals, St. Louis,MO). For collagen I or collagen IV, plates were coated for 2
h as per manufacturer’s instructions (Becton Dickinson Labware, Bedford, MA).
Cells (7  104) were added to the wells in serum-free conditions, incubated for
indicated times at 37-C, and the unbound cells were then washed away. The
adherent cells were stained with toluidine blue, lysed with 2% SDS (Biowhit-
taker, Walkersville, MD), and quantitated by the absorbance at 595 nm. Binding
to each extracellular matrix protein was performed in triplicate, and the mean and
standard deviation were calculated. Each experiment was repeated at least three
times, and groups were compared using an unpaired Student’s t test.
In antibody blocking experiments, cells were preincubated with various
dilutions ofmAbs for 60min at 4-C. Cells (7 104) were aliquoted into a 96-well
plate precoated with laminin or poly-d-lysine. Each experiment was at least
repeated five times.
Quantitation of EMP2 and b3 integrin levels
In order to estimate the difference in EMP2 and h3 integrin levels, HEC1A-
GFP and HEC1A-hEMP2 cells were resuspended at 1 104 cells/Al in Laemmli
buffer. The cell number equivalents of HEC1A-GFP and HEC1A-hEMP2 were
then titrated by serial two-fold dilutions and separated by SDS-PAGE. Blots were
analyzed for EMP2 and h3 levels expression. As EMP2 contains multiple
glycosylation sites (Wang et al., 2001), N-linked glycans were cleaved using
PNgase (New England Biolabs, Beverly, MA). Eluates were treated as per
manufacturer’s instructions at 37-C for 2–3 h. Experiments were repeated at
least three times independently, and results of the different experiments were used
to determine means and standard errors for each group. Groups were compared
using an unpaired Student’s t test.
Flow cytometry
The membrane expression of a1, a2, a4, a5, a6, and avh3 integrin subunits
was assessed by flow cytometry. Cells were fixed in 2% paraformaldehyde (w/v)
in PBS for 20 min on ice. Cells were incubated with primary antibody for 30 min
on ice in PBS + 2% FCS. The cells were washed two times and incubated with R-
PE-conjugated anti-rat Ig, n light chain antibody or an R-PE-conjugated anti-
mouse IgG antibody for 30 min on ice (BD Biosciences). R-PE was used at 0.25Ag/million cells. As a negative control, cells were incubated with secondary
alone. After two consecutive washes, cells were resuspended in PBS and
analyzed with a FACScan flow cytometry (BD Biosciences). Integrin expression
levels were calculated as mean fluorescent intensity (MFI).
Northern blot analysis
Total RNAwas isolated from cells using the Qiagen RNeasy RNA isolation
kit and RNeasy MinElute RNA cleanup kit according to the manufacturers’
instructions. RNA (10 Ag) was subjected to denaturing agarose gel electropho-
resis and transferred to Hybond-XL nylon membrane (Amersham Biosciences)
by capillary action and cross-linked by UV irradiation (Stratalinker; Stratagene,
San Diego, CA). Using HEC1A cDNA, a 495 bp human beta 1 integrin probe
was produced by PCR using 5V-CAGAGAAGCTCAAGCCAGAGG-3V (sense)
and 5V-CTCCAGCCAATCAGTGATCCAC-3V (antisense) oligonucleotides (30
cycles, annealing 50-C). A 539 bp human beta 3 integrin probe was produced
under the same conditions with 5V-GTGACCTGAAGGAGAATCTGCTG-3V
(sense) and 5V-CATCTCGGTTCCGTGACACAC-3V (antisense). A human
GAPDH probe was produced as previously described (Wadehra et al., 2002a).
Purified PCR products were labeled using a random primer labeling kit
(Stratagene) with [32P]dCTP (Amersham Biosciences). Membranes were
prehybridized with Rapid-Hyb buffer (Amersham Biosciences) for 1 h and
hybridized with labeled probe overnight. Blots were then washed twice in 2
SSC and 0.1% SDS for 10 min at 65-C and then twice more in 0.1 SSC and
0.1% SDS for 10 min at 65-C and exposed to X-ray film.
Inhibition of uterine EMP2 expression in vivo
Liposome-mediated plasmid transfection in vivo was described previously
(Wadehra et al., submitted for publication). DNA–liposomes were prepared
immediately prior to transfection surgery by mixing the plasmid DNA with
FuGENE 6 (Roche Molecular Biochemicals, Indianapolis, Indiana) in a 1:3
(Ag:Al) ratio per manufacturer’s instructions, incubated for 15 min, and finally
volume-adjusted with sterile PBS so the desired amount of DNA could be
injected in a final volume of 100 Al. In the afternoon of day 1 pc, females were
anaesthetized, and the distal portion of each uterine horn was identified via
small flank incisions. The uterine horns each was slowly injected via a 30-G
needle with 100 Al of the appropriate DNA–liposome mixture. Luminal
placement of the injected fluid was confirmed by observation of slight
distension of the visible portion of the uterine horn. Of note, in test experiments
on CF1 mice in which the entire reproductive tract was exposed via an
abdominal incision, the capacity of a uterine horn was only about 20 Al.
Injected fluid above this volume leaked rapidly into the vagina. When
injections were performed with Coomassie Blue dye to track the injected
fluid, no dye was observed to enter the contralateral uterine horn. However,
because of the possibility of crossover of the fluid into the opposite uterine
horn, the first horn injected was the ‘‘treatment’’ horn, and the second horn was
injected with the control DNA so that any crossover fluid would be washed out
of the control horn. This method was chosen over using different mice for each
type of DNA so that each mouse could serve as its own internal control.
To assess the efficacy of the transfected plasmids in reducing EMP2
expression, females were euthanized 4 days after transfection (day 5 postcoitum
[pc]), and the uteri were processed for immunohistochemistry using mEMP2
antisera or the corresponding preimmune control. Sections from the same tissue
blocks were then stained for h3 integrin as outlined below.
Immunohistochemistry
Uterine tissue was fixed in 10% formalin, embedded in paraffin, and
sectioned at 5 Am. Slides were incubated in 0.1 M citrate pH 6.0 at 95-C for 20
min to improve antigen exposure. Samples were incubated with h3 antiserum
(1:50), EMP2 antisera (1:250), or a rabbit serum control at the same dilution
and then incubated with the Vectastain ABC kit (Vector Labs, Burlingame, CA)
according to manufacturer’s instructions. EMP2 expression was detected using
Vector VIP (Vector Labs), with methyl green used as a counterstain. h3 integrin
staining was visualized using diaminobenzidine HCl (DAB; Vector Labs), and
nuclei were counterstained in Mayer’s hematoxylin (DAKO).
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HEC1A cells (1  107) were plated overnight in 100 mm dishes (Corning,
Corning, NY). Cells were washed 2 times with PBS, lysed (1% Nonidet P-40
containing 2 mM phenylmethylsulfonyl fluoride, 10 Ag/ml aprotinin, 2 Ag/ml,
pepstatin, 10 mM iodoacetamide, 0.1 mM EDTA, 0.1 mM EGTA, 10 mM
HEPES, and 10 mM KCl) for 30 min at 4-C, and then sonicated for 15 s. Cell
lysates were precleared by incubation with Protein A agarose beads (Santa Cruz
Biotechnology, Santa Cruz, CA) and then incubated overnight with agarose
beads bound to either anti-EMP2 rabbit polyclonal antibodies or an anti-h3
mAb. The beads were washed 3–4 times in lysis solution and finally in 50 mM
Tris, pH 8 buffer. Immune complexes were eluted from the beads using
Laemmli sample buffer (62.5 mM Tris–Cl, pH 6.8, 10% glycerol, 2% SDS,
0.01% bromophenol blue, 2% h-mercaptoethanol). Samples were analyzed
using Western blot analysis as described above.
Results
Characterization of integrins in HEC1A cells
The human endometrial carcinoma cell line HEC1A has been
shown to be permissive for blastocyst attachment (Wadehra et
al., submitted for publication). As an initial assessment, weFig. 1. Expression of integrins in HEC1A cells. HEC1A cells were fixed and staine
alone is indicated by the black line. Flow cytometry was used to quantitate the mecharacterized the expression of integrins on HEC1A thought to
be important for blastocyst attachment. The surface expression
of avh3, avh5, a6, h1, h4, a5, a4, a2, and a1 was determined
by flow cytometry. HEC1A cells express high levels of avh3,
h1, and a6 integrins. Moderate to low levels were observed for
avh5,h4, a5, anda1 integrins (Fig. 1). Expression ofa4 and a2
integrins was below the limit of detection (data not shown). It
should be noted that this assessment does not compare absolute
integrin isoforms since the relative levels are in part affected by
characteristics of anti-integrin antibodies.
EMP2 promotes avb3 integrin surface expression
EMP2 selectively modulates expression of integrin isoforms
in other cell types. To test the effect of EMP2 on integrin
expression in endometrial cells, stable transfectant cell lines
were generated that ectopically overexpressed EMP2 (HEC1A-
hEMP2), expressed a vector control (HEC1A-GFP), or
expressed a ribozyme to decrease EMP2 expression (HEC1A-
hRZ2). By Western analysis, EMP2 expression in HEC1A-
hEMP2 and HEC1A-hRZ2 was 8.7-fold and 0.2-fold of vectord for integrins avh3, a6, h1, h4, a1, a4, and a5. Secondary antibody staining
an fluorescent intensity (MFI).
Fig. 2. Recombinant modification of EMP2 expression levels. Steady state
protein levels of EMP2 were measured by Western blot analysis in HEC1A-
GFP (control cells), HEC1A-hEMP2 cells (high EMP2), and HEC1A-hRZ2
cells (minimal EMP2). Bands corresponding to GFP-EMP2 fusion protein
(48 kD) and native EMP2 (20 kD) are indicated. Experiments were performed
independently at least three times with similar results.
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stained for avh3, avh5, h1, or av h5 integrins and analyzed by
flow cytometry (Fig. 3). EMP2 expression specifically enhanced
the surface expression of avh3 integrin, while the ribozyme
decreased avh3 expression (Fig. 3A). HEC1A-hEMP2 cells
expressed 50% more avh3 integrin on their surface (MFI,
64.3) compared to vector control (MFI, 43.2) or cells lacking
EMP2 (MFI, 39.7). In contrast, modulation of EMP2 expression
had no effect on the surface expression of integrin avh5 or the
h1 integrin subunit (Figs. 3B–C). Similarly, alterations in EMP2Fig. 3. The expression level of EMP2 alters surface levels of avh3 integrin in HEC1
vector control (HEC1A-GFP; B and E), or minimal (HEC1A-hRZ2; C and F) le
visualized using an R-PE-conjugated anti-rat Ig, n light chain antibody. The MF
histogram.levels did not alter the levels ofh4,a1,a5, or a6 integrin surface
expression (data not shown).
Modulation of EMP2 expression alters extracellular matrix
binding
One important function of integrins is to orchestrate binding
to extracellular matrix proteins. To validate the functional
effect of EMP2 expression levels on integrin ligand specificity,
HEC1A-GFP, HEC1A-hEMP2, and HEC1A-hRZ2 were tested
for their binding avidity to different extracellular matrix
proteins. As shown in Fig. 4A, the expression of EMP2
regulated the ability of HEC1A cells to bind fibronectin.
HEC1A-hEMP2 exhibited a 2-fold increase in fibronectin
binding compared to vector control cells and a 4-fold increase
in fibronectin binding compared to HEC1A-hRZ2. The
differences between HEC1A-hEMP2 and HEC1A-GFP (P <
0.05) and between HEC1A-GFP and HEC1A-hRZ2 (P =
0.005) were significant. Moreover, the regulation of fibronectin
binding by EMP2 was specific as no significant differences in
laminin or collagen I binding were observed among the three
cell types (Fig. 4B).
Fibronectin binding is mediated by a variety of integrin
pairs and non-integrin receptors such as lectins (Belkin and
Stepp, 2000). To verify that the fibronectin binding observed in
HEC1A cells was mediated by integrin avh3, we tested
whether adhesion to extracellular matrix proteins was blocked
by anti-avh3 integrin antibodies (Fig. 4C). Cells wereA cells. HEC1A cells expressing EMP2 at elevated (HEC1A-hEMP2; A and D),
vels were stained with an anti-avh3 (A–C) or anti-a6 (D–F). Staining was
I was quantitated by flow cytometry and tabulated in the top corner of each
Fig. 4. EMP2 expression selectively augments avh3-dependent fibronectin binding. (A and B) Cells (HEC1A-GFP, HEC1A-hEMP2, and HEC1A-hRZ2) were
incubated at 37-C for 20 min in wells coated in serum-free buffer with fibronectin (A), laminin (B), or collagen I (B); BSA was used as a negative control protein.
Wells were washed to remove unbound cells. Adherent cells were stained with toluidine blue, lysed in 2% SDS, and enumerated at an absorbance of 595 nm. Poly-d-
lysine binding was used to normalize for plating differences between the cell types. Values are mean T SD for triplicate wells. *P = 0.004; **P = 0.005 (Student’s
unpaired t test). (C) HEC1A-hEMP2 cells were incubated with antibodies to avh3, a6, or a5 for 1 h. Cells were added to wells containing fibronectin (D) or
polylysine to normalize values (data not shown). Cells were assayed for binding as described above. A representative experiment is shown; three independent
experiments yielded similar results.
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control), or a6 (negative control) integrin and allowed to
adhere to a 96-well fibronectin-coated plate for 25 min. We
observed that only avh3 integrin antibodies specifically and
completely abolished the binding of HEC1A-GFP and
HEC1A-hEMP2 cells to fibronectin-coated plates. These
findings indicate that integrin avh3 serves as the predominant
fibronectin-binding receptor in both wildtype and EMP2-
overexpressing HEC1A cells. Thus, the increase in fibronectin
binding caused by EMP2 was avh3-dependent.
Coordinate expression of EMP2 and b3 integrin during the
window of implantation
As both EMP2 and h3 integrin are necessary for successful
implantation, we hypothesized that the two proteins might
colocalize. Mice were hyperstimulated, mated, and uteri were
collected every 24 h until day 6 pc. The expression pattern of
EMP2 at day 1 pc was perinuclear, while h3 integrin
expression was generally negative in luminal epithelium (Fig.
5A, left). By day 3, h3 integrin was up-expressed, and its
distribution relative to EMP2 was fully concordant. Thus, the
cellular localization of EMP2 and h3 integrin on day 3 pc was
diffuse, with staining throughout the cytosol (Fig. 5A, middle).
By day 5 pc, both proteins had established a prominent apical
surface distribution on the luminal epithelium (Fig. 4A, right).
No staining was observed in tissue stained with control serum
(data not shown).
Biochemical association of EMP2 and b3 integrin
Since EMP2 and h3 integrin colocalized in native epi-
thelium, we tested the idea that they might exist in a
biochemical association by coimmunoprecipitation. HEC1A
cell lysates were prepared in non-ionic detergent (1% Nonidet
P-40), sedimented at 300  g to remove nuclei, immunopre-cipitated with anti-EMP2 or anti-h3 integrin, and detected by
Western immunoblots for the cognate or reciprocal proteins
(Fig. 5B). As expected, anti-EMP2 pulled down EMP2;
comparison with direct assay of equivalent cell lysate
indicated that the immunoprecipitation was quantitative.
However, anti-EMP2 also quantitatively pulled down h3
integrin (Fig. 5B, left). Similarly, anti-h3 integrin quantita-
tively pulled down both h3 integrin and EMP2 (Fig. 5B,
right). Notably, this association occurred in the presence of 1%
Nonidet P-40, which is a relatively strong non-ionic detergent
that does not sustain nonspecific hydrophobic interactions
observed with 4-TM proteins in the presence of detergents like
Brij 97 or CHAPS (Knobeloch et al., 2000; Lagaudriere-
Gesbert et al., 1997; Levy and Shoham, 2005; Wadehra et al.,
2004). These findings suggest that the EMP2 can associate
with the h3 integrin subunit and that a large fraction of these
proteins may exist in a complex containing both molecular
species.
EMP2 expression increases total b3 integrin protein levels
The preceding sections showed that EMP2 associates with
h3 integrin and that modified EMP2 expression alters levels of
avh3 integrin surface expression. To determine if EMP2
influences total protein levels of this integrin isoform, Western
blot analysis was performed. Lysates were analyzed for EMP2,
avh3 integrin, h3 integrin, h1 integrin, and h-actin expres-
sion. EMP2 overexpression selectively increased total h3
integrin levels but did not alter h1 or h-actin protein
expression (Fig. 6A). The commercially available antibody
for avh3 integrin was unsuitable for Western analysis (data
not shown), so h3 integrin was used as a surrogate for this
integrin species.
To quantitate the ratio of h3 integrin to EMP2 expression,
titrations of equivalent cell lysates by Western blot analysis
were performed (Fig. 6A, and data not shown). HEC1A-
Fig. 6. EMP2 alters the levels of h3 integrin protein andmRNA. (A) Steady state
protein levels ofh3,h1, andh-actin (control for equal loading)weremeasured by
Western blot analysis in cells with varying levels of EMP2 protein. (B) Steady
state mRNA levels of h3 integrin, h1 integrin, and GAPDH (control for equal
loading)measured byNorthern blot analysis. Compared to control cells (HEC1A-
GFP),h3 integrin levels were elevated in HEC1A-hEMP2 cells (high EMP2) and
reduced in HEC1A-hRZ2 cells (minimal EMP2). h3 integrin expression was
more dynamically affected in the protein vs. mRNA compartments. EMP2
expression levels had no influence on h1 integrin expression. Experiments were
performed independently at least three times with similar results.
Fig. 5. Association of EMP2 and h3 integrin. (A) EMP2 and h3 integrin expression was detected in hyperstimulated mice on days 1, 3, and 5 pc. Images were
stained with either EMP2 antisera (top) or h3 integrin (bottom) Magnification: 400. (B) Coimmunoprecipitation experiments were performed in HEC1A cells. 1 
107 HEC1A cell lysates were immunoprecipitated with anti-EMP2 or anti-avh3 integrin in the presence of 1% Nonidet P-40. Negative controls were appropriate
isotype control IgG antibodies (‘‘Isotype’’). Test and control precipitates were loaded on SDS-PAGE gels; equivalent amounts of cell lysates used for
immunoprecipitation were directly loaded in adjacent lanes to estimate total EMP2 and h3 integrin levels (‘‘Lysate’’). Samples were fractionated by SDS-PAGE,
Western blotted, and replicate filters were probed with anti-EMP2 or anti-h3 integrin. EMP2 was detected Vector VIP with methyl green counterstain. h3 integrin
was detected with DAB, and nuclei were counterstained with Mayer’s hematoxylin.
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integrin compared to vector control cells. This correlated
with an increase in EMP2 (GFP-EMP2 fusion protein plus
native EMP2) of 8.7-fold (T0.7 SEM) in HEC1A-hEMP2
cells versus native EMP2 in vector control cells (Fig. 2).
These results indicated the quantitatively proportional
changes in EMP2 and h3 integrin levels. Since EMP2 and
avh3 integrin appear to exist as physical complexes (see
preceding section), this proportionality suggests that avh3
integrin levels may be limited by the EMP2 available to
form ternary complexes.
EMP2 expression alters b3 integrin mRNA levels
We have shown that EMP2 expression selectively altered the
total protein levels forh3 integrin, but noth1 integrin. In order to
determine if EMP2 expression altered the mRNA steady state
levels of integrin subunits, Northern blots were performed on
populations of HEC1A, HEC1A-hEMP2, and HEC1A-hRZ2
cells. Analysis revealed no significant differences in the
Fig. 7. Inhibition of EMP2 expression reduces avh3 integrin expression in vivo. Uterine horns were transfected on day 1 pc with 5 and 10 Ag GFP (A, B), mRZ1 (E,
F), h-shRNA (C, D) or m-shRNA (G, H). The uterine horns were excised on day 5 pc and processed by immunohistochemistry with avh3 integrin antibody.
Magnification: 400.
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reduction in EMP2 expression by ribozyme cleavage reduced
the steady state mRNA levels of h3 integrin by two-fold over
cells expressing EMP2 (HEC1A and HEC1A-hEMP2). No
significant differences were observed between control HEC1A
cells and HEC1A-hEMP2. These data suggested that the
increase in h3 integrin protein levels in HEC1A-hEMP2 cells
might result from decreased turnover of the protein, whereas the
decrease in integrin h3 levels in HEC1A-hRZ2 cells might result
from a decrease in either the stability or transcription of integrin
h3 mRNA. However, further study is necessary to establish the
mechanism of these EMP2 effects on h3 expression.
EMP2 expression controls avb3 integrin expression in vivo
avh3 integrin expression appears to be regulated by EMP2
in vitro. To determine if this control occurred in vivo, we
utilized ribozyme- and RNA interference-mediated techniques
to knock down expression of EMP2 in mouse uterine horns and
then examined the effect of decreasing EMP2 on the expression
of avh3 integrin in the same tissue. This approach allowed us
to examine the relationship between EMP2 and avh3 integrin
expression in the setting of the living mouse uterus, in the
presence of physiologically relevant amounts of hormones,
cytokines, and growth factors that normally control endome-
trial protein expression. Mouse uterine horns were transfected
on day 1 pc with expression plasmids encoding a mouse
EMP2-specific ribozyme (pEGFP-mRZ1), shRNA targeting
mouse EMP2 (m-shRNA), or control vectors (h-shRNA for
human EMP2 shRNA; or pEGFP for GFP alone). Previous
results demonstrated that the pEGFP-mRZ1 and m-shRNA
plasmids were effective in reducing EMP2 expression in vivo
by day 5 pc (Wadehra et al., submitted for publication).
Similarly, avh3 integrin expression on day 5 pc wassignificantly reduced when uteri were treated with the
pEGFP-mRZ1 and m-shRNA plasmids (Figs. 7E–H). In
contrast, uteri treated with a vector control (Figs. 7A–B) or
h-shRNA, which does not target mouse EMP2 (Figs. 7C–D),
exhibited intense membrane avh3 integrin staining in both
luminal and glandular epithelium. Inhibition of avh3 integrin
expression appeared to be EMP2 dose-dependent as only
partial inhibition was observed in uteri treated with 5 Ag of
pEGFP-mRZ1 or m-shRNA. No staining was observed in
tissue transfected with pEGFP-mRZ1 or m-shRNA and then
processed using control serum (data not shown).
Discussion
Endometrial expression of EMP2 is required for blastocyst
implantation, and EMP2 is known to control surface expression
of certain integrin isoforms in model cell types. Since
endometrial avh3 integrin is thought to play a role in
blastocyst implantation, this study tested the prediction that
EMP2 controlled expression of this integrin isoform in
endometrial cells. We observed that among several integrin
isoforms, avh3 expression was selectively dependent on
EMP2 levels. That is, recombinant up- and down-regulation
of EMP2 resulted in up- and down-expression of avh3. This
phenotype was observed both in an endometrial cell line and in
native endometrium, indicating that this role of EMP2 is a
physiologic feature of the endometrial cell.
One issue raised by these findings is the level of integrin
regulation affected by EMP2. Recombinant manipulation of
EMP2 (a 40-fold range spanning ribozyme knockdown and
EMP2 overexpression) showed that levels of h3 integrin total
protein changed in direct proportion to EMP2 levels.
Somewhat in contrast, levels of avh3 integrin at the cell
surface coordinately changed, but with a much smaller
M. Wadehra et al. / Developmental Biology 287 (2005) 336–345344dynamic range (3-fold span). The present study shows that
EMP2 and avh3 integrin largely reside in an overlapping
post-Golgi intracellular compartment and exist as physical
complexes by biochemical criteria. These observations suggest
that EMP2 influences avh3 integrin levels in the intracellular
compartment, perhaps because the stability of avh3 integrin
may be limited by the EMP2 available to form ternary
complexes.
A similar conclusion was made regarding EMP2 and a6
integrin in mouse NIH3T3 fibroblasts (Wadehra et al., 2002b,
2004). Curiously, enforced alteration of EMP2 expression did
not affect a6 integrin surface levels in HEC1A cells. This
might reflect distinctions in species-specific (human vs. mouse)
or tissue-specific (endometrial vs. fibroblast) properties of the
a6 integrin isoform or other molecules involved in the net
trafficking fate of this isoform.
Recombinant manipulation of EMP2 also caused quantita-
tively similar changes in levels of h3 integrin mRNA. This
suggests that EMP2 might control avh3 expression at the
transcriptional level. This would be surprising since EMP2 is a
membrane protein mainly localized to plasma membrane and
post-Golgi compartments. 4-TM proteins including EMP2 are
thought to form the nidus of multi-receptor signaling com-
plexes required for efficient integration of receptor-mediated
triggering and control of signal pathway activity (Knobeloch et
al., 2000; Lagaudriere-Gesbert et al., 1997; Levy and Shoham,
2005; Little et al., 2004; Wadehra et al., 2004). Accordingly, it
is possible that modulation of EMP2 might impair the
efficiency of certain signaling pathways that maintain h3
integrin transcription in the endometrium. However, diverse
mechanisms govern integrin expression, including regulation
of protein levels by transcriptional or posttranscriptional
events, mRNA alternate splicing, and mobilization of preexist-
ing stores (Hemler, 1998; Porter and Hogg, 1998; Shimaoka et
al., 2002). In particular, a integrin subunit levels are rate-
limiting in the integrin heterodimer expression, and reduced
avh3 expression results accelerate h3 mRNA decay (Retta et
al., 2001). Thus, altered h3 mRNA levels may be a
consequence rather than cause of EMP2-induced changes in
avh3 protein. Accordingly, the mechanism(s) of EMP2 control
of avh3 expression will benefit from more detailed study.
A second issue is whether these EMP2-induced changes in
integrin levels alter avh3 integrin function in endometrial cells.
Quantitative changes in integrin levels do not simply relate to
integrin function since integrin surface delivery is tightly
regulated from the much larger cytoplasmic integrin pool and
because of the conversion and stability of the activated
conformation state for high avidity binding and efficient
signaling (Dalton et al., 1992; Sastry et al., 1996). At a
functional level, these post-translational factors might augment
or compensate for the changes in avh3 integrin total protein
levels induced by EMP2. However, using fibronectin binding
as a readout of avh3 integrin function, we found that function
was indeed correlated with quantitative changes in avh3
integrin levels. Endometrial binding to fibronectin, vitronectin,
and osteopontin is thought to play an important role in
implantation (Nejjari et al., 1999; Sorokin et al., 2000). So,EMP2-induced control of avh3 integrin in endometrial cells
may in part account for the requirement of EMP2 in
endometrial implantation competence.
Endometrial implantation competence is dictated by an
integrated set of cell functions, of which avh3 integrin is only
one component. In addition to avh3 and its counterligands,
several receptor–ligand pairs are involved with blastocyst–
endometrial interaction (including l-selectin, HB-EGF, and
LPA3) (Dey et al., 2004; Genbacev et al., 2003; Liu and
Armant, 2004; Raab et al., 1996; Ye et al., 2005; Yoo et al.,
1997). In addition, some of these interaction molecules act
pleiotropically. For example, HB-EGF and EGF produced by
the endometrium act both on the blastocyst and as paracrine
molecules for decidualization, proliferation, and survival of
endometrial epithelium and stroma. Accordingly, endometrial
EMP2 is one new factor in a larger biologic palette of
endometrial function involved in implantation. Clues to the
integration of these elements are beginning to emerge, such as
the regulation by HB-EGF and EGF receptors of avh3 integrin
expression, and the regulation by 4-TM proteins of EGF and
HB-EGF expression and cognate receptor signaling (Chobo-
tova et al., 2005; Lessey et al., 2002, 2003; Raab et al., 1996;
Tan et al., 2004). The present paper highlights a pattern of
expression and regulation that links EMP2 and avh3 integrin
in the endometrium, and the integration of avh3 integrin into
the larger palette may in part account for the role of EMP2 in
implantation competence.
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